ZR-MTX for Newly Diagnosed Eye Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, zanubrutinib and methotrexate, for people with a newly diagnosed lymphoma that affects only the eyes. The goal is to see if this treatment works well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with lymphoma in the eye (vitreoretinal lymphoma) that has not spread to the brain or other parts of the body.
- You are able to take care of yourself (ECOG score of 0, 1, or 2).
- Your kidneys work well enough (a test called creatinine clearance of 60 or higher).
- Your liver function is normal or only mildly abnormal.
- You do not have any serious infections, other cancers, or heart failure.
- If you could become pregnant, you must use effective birth control during the study. If you are a man, you must use condoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
This trial tests a treatment for primary vitreoretinal lymphoma, a rare eye cancer. It aims to see if the drug methotrexate can help patients with this condition.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial tests a new drug called zanubrutinib combined with standard chemotherapy for people newly diagnosed with a type of brain lymphoma. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a combination of a targeted drug (Orelabrutinib) and radiation therapy for adults newly diagnosed with a slow-growing lymphoma around the eye. The goal is to see if this approach works well and is safe for people who have not had treatment before.
This trial tests a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) as the first treatment for marginal zone lymphoma that has spread or is advanced. The goal is to see if this combination is effective and safe for patients who have not had prior treatment.
Hear when a new Primary Intraocular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.